Expression and amplification of therapeutic target genes in retinoblastoma

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 243, Issue 2, 2005, Pages 156-162

  Bösch, Doris ^a,b   Pache, Mona ^a,c   Simon, Ronald ^b   Schraml, Peter ^b   Glatz, Katharina ^b   Mirlacher, Martina ^b   Flammer, Josef ^a   Sauter, Guido ^b   Meyer, Peter ^a,b  

^a UNIVERSITY EYE CLINIC   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; PARAFFIN; STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER CYTODIAGNOSIS; CANCER INHIBITION; CANCER SURVIVAL; CHILD; DIAGNOSTIC VALUE; DRUG INDICATION; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RETINOBLASTOMA; RISK REDUCTION; TISSUE MICROARRAY; TISSUE PREPARATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 14944372537     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-004-1036-2     Document Type: Article

References (40)

1. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 7:31-39 1:CAS:528:DC%2BD38XnsFOiurg%3D
2. Arteaga CL, Johnson DH (2001) Tyrosine kinase inhibitors - ZD1839 (Iressa). Curr Opin Oncol 13:491-498 10.1097/00001622-200111000-00012
3. Arteaga CL, Moulder SL, Yakes FM (2002) HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 29:4-10 10.1053/sonc.2002.34047
4. Barton J, Blackledge G, Wakeling A (2001) Growth factors and their receptors: New targets for prostate cancer therapy. Urology 58:114-122 10.1016/S0090-4295(01)01253-5
5. Beck MN, Balmer A, Dessing C, Pica A, Munier F (2000) First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 18:2881-2887 1:STN:280:DC%2BD3cvitFelsw%3D%3D
6. Blackledge G, Averbuch S, Kay A, Barton J (2000) Anti-EGF receptor therapy. Prostate Cancer Prostatic Dis 3:296-302 10.1038/sj.pcan.4500488
7. Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, Naldi N, Cascinu S (2002) HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 13:1398-1403 10.1093/annonc/mdf217
8. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G (2002) Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol 38:411-415 10.1002/mpo.1355
9. Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP (1999) Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806 1:CAS:528:DyaK1MXht1Sjurc%3D
10. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145 1:CAS:528:DC%2BD3cXnt1ygur4%3D
11. Finger PT, Czechonska G, Demirci H, Rausen A (1999) Chemotherapy for retinoblastoma: A current topic. Drugs 58:983-996 1:CAS:528:DC%2BD3cXpt1Orug%3D%3D
12. Fink-Puches R, Pilarski P, Schmidbauer U, Kerl H, Soyer HP (2001) No evidence for c-erbB-2 overexpression in cutaneous melanoma. Anticancer Res 21:2793-2795 1:CAS:528:DC%2BD3MXovVyjsr4%3D
13. Forseen SE, Potti A, Koka V, Koch M, Fraiman G, Levitt R (2002) Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors. Anticancer Res 22:1599-1602 1:CAS:528:DC%2BD38XmsFWks7s%3D
14. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96:925-932 1:CAS:528:DC%2BD3cXltlKitLw%3D
15. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3:655-664 10.1016/S1470-2045(02)00899-9
16. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258:818-821 1:CAS:528:DyaK3sXhs1Gn
17. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847 1:CAS:528:DyaK1cXktlKntr8%3D
18. Kuttan NA, Bhakthan NM (1997) Epidermal growth factor receptor (EGFR) in oral squamous cell carcinomas: Overexpression, localization and therapeutic implications. Indian J Dent Res 8:9-18 1:STN:280:DyaK1c7ls1amsA%3D%3D
19. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M (1999) Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154:53-60 1:CAS:528:DyaK1MXnsFCqtg%3D%3D
20. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, Sobin LH, Miettinen M (2000) Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157:1091-1095 1:CAS:528:DC%2BD3cXnsVKjtbg%3D
21. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741-1744 10.1182/blood.V99.5.1741
22. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F, Buhl R (2001) c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 92:474-479 10.1002/ijc.1229
23. Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12 10.1007/s004280000338
24. Miettinen M, Sarlomo-Rikala M, Lasota J (1998) Gastrointestinal stromal tumours. Ann Chir Gynaecol 87:278-281 1:STN:280:DyaK1M7gvV2itg%3D%3D
25. Moch H, Sauter G, Gasser TC, Bubendorf L, Richter J, Presti JC Jr, Waldman FM, Mihatsch MJ (1998) EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol 184:424-429 10.1002/ (SICI)1096-9896(199804)184:4<424::AID-PATH1223>3.3.CO;2-1
26. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154:981-986 1:STN:280:DyaK1M3lt1CisQ%3D%3D
27. Murphree AL, Villablanca JG, Deegan WF III, Sato JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ (1996) Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114:1348-1356 1:CAS:528:DyaK28Xnt1Kmsr4%3D
28. Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194:349-357 10.1002/ 1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D
29. van Oosterom AT, Judson I, Verweij J, Stroobants S, di Paola ED, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423 10.1016/S0140-6736(01)06535-7
30. van Oosterom AT, Judson IR, Verweij J, Stroobants S, Dumez H, di Paola DE, Sciot R, Van Glabbeke M, Dimitrijevic S, Nielsen OS (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: A report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38:S83-S87 10.1016/S0959-8049(02)80608-6
31. Persons DL, Arber DA, Sosman JA, Borelli KA, Slovak ML (2000) Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma. Anticancer Res 20:1965-1968 1:CAS:528:DC%2BD3cXlvFCrurc%3D
32. Sauter G, Moch H, Moore D, Carroll P, Kerschmann R, Chew K, Mihatsch MJ, Gudat F, Waldman F (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53:2199-2203 1:STN:280:ByyB2M7ktlI%3D
33. Sauter G, Moch H, Gasser TC, Mihatsch MJ, Waldman FM (1995) Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry 21:40-46 1:STN:280:BymC3c%2Fgtlc%3D
34. Scholes AG, Hagan S, Hiscott P, Damato BE, Grierson I (2001) Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma. Arch Ophthalmol 119:373-377 1:STN:280:DC%2BD3M7msVOkuw%3D%3D
35. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5:1966-1975 1:STN:280:DyaK1MvgtVSmsA%3D%3D
36. Shields CL, Shields JA (1999) Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 36:8-18 (quiz 35-16) 1:STN:280:DyaK1M7jvVCmtA%3D%3D
37. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ (2002) Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 120:1653-1658 12470138
38. Tamboli A, Podgor MJ, Horm JW (1990) The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol 108:128-132 1:STN:280:By%2BC387gsFc%3D
39. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249-2256 1:CAS:528:DC%2BD38Xhslejtg%3D%3D
40. Wilson MW, Czechonska G, Finger PT, Rausen A, Hooper ME, Haik BG (2001) Chemotherapy for eye cancer. Surv Ophthalmol 45:416-444 10.1016/ S0039-6257(00)00210-1